Nivolumab plus ipilimumab has shown clinical benefit in nonrandomized studies of MSI-H or dMMR metastatic colorectal cancer. In this phase 3 open-label trial, we randomly assigned patients with ...
Fig 1. Patient flow. IPI, ipilimumab; NIVO, nivolumab. Median follow-up for OS was 43.6 months (range, 0.1-108.2) for the total pooled population, 45.0 months (range, 0.1-99.0) for NIVO + IPI, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback